With 1.86 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.77 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $18.12 whereas the lowest price it dropped to was $17.2. The 52-week range on PGNY shows that it touched its highest point at $42.08 and its lowest point at $13.39 during that stretch. It currently has a 1-year price target of $18.86. Beta for the stock currently stands at 1.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PGNY was up-trending over the past week, with a rise of 3.14%, but this was up by 17.14% over a month. Three-month performance surged to 6.93% while six-month performance fell -38.30%. The stock lost -51.11% in the past year, while it has gained 1.04% so far this year. A look at the trailing 12-month EPS for PGNY yields 0.58 with Next year EPS estimates of 0.59. For the next quarter, that number is 0.09. This implies an EPS growth rate of -13.23% for this year and 10.59% for next year.
Float and Shares Shorts:
At present, 88.34 million PGNY shares are outstanding with a float of 71.16 million shares on hand for trading. On 2024-12-13, short shares totaled 12.2 million, which was 1433.0000000000002 higher than short shares on 1731628800. In addition to Mr. David J. Schlanger J.D. as the firm’s Executive Chairman, Mr. Peter Anevski CPA serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 1.07629 of PGNY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PGNY reported revenue of $286625000.0 and operating income of $12458000.0. The EBITDA in the recently reported quarter was $13295000.0 and diluted EPS was $0.11.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PGNY since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PGNY analysts setting a high price target of 22.0 and a low target of 17.0, the average target price over the next 12 months is 18.85714. Based on these targets, PGNY could surge 26.22% to reach the target high and fall by -2.47% to reach the target low. Reaching the average price target will result in a growth of 8.19% from current levels.
Analysts have provided yearly estimates in a range of $0.58359 being high and $0.46505 being low. For PGNY, this leads to a yearly average estimate of $0.538.
